Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

289.39 -3.50 (-1.19%)
Streaming Delayed Price Updated: 3:20 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
News headline image
Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
From Insulet Corporation
Via Business Wire
News headline image
Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia
From Insulet Corporation
Via Business Wire
News headline image
Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks ↗
The deal would have been transformative, but may have limited teamwork in the space. 
Via Investor's Business Daily
News headline image
Looking Into Insulet's Return On Capital Employed ↗
According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4. 
Via Benzinga
News headline image
Expert Ratings for Insulet ↗
Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings: 
Via Benzinga
News headline image
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space ↗
One analyst called the rumored deal "transformative," but says the timing is unfavorable. 
Via Investor's Business Daily
News headline image
PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition ↗
Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company. 
Via InvestorPlace
News headline image
Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ↗
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning! 
Via InvestorPlace
News headline image
Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know ↗
Citigroup has decided to maintain its Buy rating of Insulet (NASDAQ:PODD) and lower its price target from $350.00 to $310.00. Shares of Insulet are trading up 1.23% over the last 24 hours, at $199.34... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday. 
Via Benzinga
News headline image
Recap: Insulet Q1 Earnings ↗
Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by... 
Via Benzinga
News headline image
Insulet Announces CEO Transition
From Insulet Corporation
Via Business Wire
News headline image
Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
News headline image
Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose
From Insulet Corporation
Via Business Wire
News headline image
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes ↗
Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with... 
Via Benzinga
News headline image
Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes
From Insulet Corporation
Via Business Wire
News headline image
Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
From Insulet Corporation
Via Business Wire
News headline image
Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20% ↗
Insulet Corp's (NASDAQ: PODD) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million, exceeding the consensus of $301.06 million. The company... 
Via Benzinga
News headline image
Recap: Insulet Q4 Earnings ↗
Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet... 
Via Benzinga
News headline image
Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year
From Insulet Corporation
Via Business Wire
News headline image
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
News headline image
Earnings Scheduled For February 23, 2022 ↗
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
News headline image
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
News headline image
Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing™: New Horizons
From Insulet Corporation
Via Business Wire
News headline image
Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine
From Insulet Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022 ↗
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.